Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.
- DOI
- 10.1016/j.jhep.2025.10.032
- Published
- 2026 Apr
- Container
- Journal of hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jhep.2025.10.032,
title = {Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.},
author = {Yoon J and Lee CK and Kim JW and Kang B and Park SJ and Kim JW and Chon HJ and Choi HJ and Lee MA and Kim TY and Oh DY},
year = {2026},
journal = {Journal of hepatology},
doi = {10.1016/j.jhep.2025.10.032},
url = {https://doi.org/10.1016/j.jhep.2025.10.032}
}RIS
TY - JOUR TI - Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. AU - Yoon J AU - Lee CK AU - Kim JW AU - Kang B AU - Park SJ AU - Kim JW AU - Chon HJ AU - Choi HJ AU - Lee MA AU - Kim TY AU - Oh DY PY - 2026 JO - Journal of hepatology DO - 10.1016/j.jhep.2025.10.032 UR - https://doi.org/10.1016/j.jhep.2025.10.032 ER -
APA
J, Y., CK, L., JW, K., B, K., SJ, P., JW, K., HJ, C., HJ, C., MA, L., TY, K., & DY, O. (2026). Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.. Journal of hepatology. https://doi.org/10.1016/j.jhep.2025.10.032
Source records
- pubmed · retrieved 2026-09-26T20:37:41.081Z